BiondVax rises on deal to develop nanosized antibody therapies
24/03/2022 11:44
** U.S.-listed shares of Israel-based pharmaceutical firm
BVXV.O rise ~61% to $2.21 before the bell - on track to hit
highest levels in nearly three months if gains hold
** BVXV agrees to develop nanosized antibody therapies with
Germany-based research firms Max Planck Society (MPG) and
University Medical Center Göttingen urn:newsml:reuters.com:*:nPn1sNzKma
** Co says target indications under deal include psoriasis,
asthma, macular degeneration, and psoriatic arthritis
** BVXV has already begun development of therapies covered
under the deal, initial preclinical results expected 2023
** Co, MPG and University Medical Center Göttingen are also
developing a nanosized COVID-19 antibody therapy under a
separate agreement urn:newsml:reuters.com:*:nPn7WsFBXa
** Up to Wednesday's close, U.S. listed shares down ~42% YTD
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))